Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.40 |
| ▸ | MMP14 | P50281 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4455362 | 0.90 | L3MBTL1 (0.53) | KDM4EL3MBTL1CCR1CCR8SLC40A1 | |
| SCHEMBL13625137 | 0.86 | L3MBTL1 (0.44) | KDM4EL3MBTL1CCR1CCR8SLC40A1 | |
| SCHEMBL13625126 | 0.85 | HSD11B1 (0.45) | KDM4EL3MBTL1CCR1CCR8SLC40A1 | |
| SCHEMBL13625120 | 0.84 | NPC1 (0.45) | KDM4EL3MBTL1CCR1CCR8SLC40A1 | |
| SCHEMBL4457946 | 0.84 | L3MBTL1 (0.47) | KDM4EL3MBTL1CCR1CCR8SLC40A1 | |
| SCHEMBL4044274 | 0.83 | L3MBTL1 (0.43) | KDM4EL3MBTL1CCR1CCR8SLC40A1 | |
| SCHEMBL13625117 | 0.83 | L3MBTL1 (0.43) | KDM4EL3MBTL1CCR1CCR8SLC40A1 | |
| SCHEMBL13625110 | 0.83 | L3MBTL1 (0.43) | KDM4EL3MBTL1CCR1CCR8SLC40A1 | |
| SCHEMBL13625138 | 0.82 | HIF1A (0.41) | KDM4EL3MBTL1CCR1CCR8SLC40A1 | |
| SCHEMBL13625135 | 0.81 | PIK3CD (0.44) | KDM4EL3MBTL1CCR1CCR8SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-04-02 | — | — | US | disclosed |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-04-02 | — | — | US | disclosed |
| US-8975278-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-03-10 | — | — | US | disclosed |
| US-8975278-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-03-10 | — | — | US | disclosed |
| US-20150025108-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | KDM4E 3604/4885L3MBTL1 3725/4885CCR1 3231/4885 |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | KDM4E 3604/4885L3MBTL1 3725/4885CCR1 3231/4885 |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | TERT, TERF2, RNGTT | KDM4E 1300/4885L3MBTL1 1268/4885CCR1 4654/4885 |
| US-20150025108-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | KDM4E 3604/4885L3MBTL1 3725/4885CCR1 3231/4885 |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | KDM4E 3604/4885L3MBTL1 3725/4885CCR1 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.